Page URL:

Cancer Genome Project releases first results

19 July 2010
Appeared in BioNews 567

The largest study to link cancer cells' genetics with their sensitivity to treatment published its first results on the 15 July.

The initial Cancer Genome Project dataset includes the responses of 350 cancer samples to 18 anticancer therapies. Among the new findings are that melanoma skin cancers, which have activating mutations in the BRAF gene, are sensitive to drugs that target the BRAF protein - a treatment already used on melanoma patients.

'It is very encouraging that we are able to clearly identify drug-gene interactions that are known to have clinical impact at an early stage in the study. It suggests that we will discover many [new] interactions even before we have the full complement of cancer cell lines and drugs screened', said Dr Ultan McDermott, a study researcher from the Wellcome Trust Sanger Institute at Cambridge, UK.

The full, five-year international study aims to find the best drug cocktails for treating a wide range of cancer types. The study team, led by researchers from the Sanger Institute and the Massachusetts General Hospital Cancer Centre in the USA, will expose 1000 different cancer cell lines to 400 anti-cancer treatments. The aim is to link drug sensitivity to measurements of mutations in key cancer genes, structural changes in the cancer cells and differences in gene activity. How a patient responds to their cancer treatment is thought to be dependent on the number and type of mutations in their cancer cells.

The new research is published on the Genomics of Drug Sensitivity in Cancer website.

Largest study of genomes and cancer treatments releases first results |  15 July 2010
New Clues to How Cancer Patients' Genes Influence Treatment
Businessweek |  15 July 2010
5 November 2012 - by Dr Nicola Davis 
Over 1,000 people from 14 countries have had their genomes mapped by scientists. The researchers say their study will help them examine genetic variations at the scale of national populations and further identification of the rare genetic variations related to many diseases...
14 March 2011 - by Dr Sarah Spain 
An international collaborative team, including Cancer Research UK scientists from the University of Dundee, has uncovered the genetic cause of a rare type of skin cancer. The condition called Ferguson-Smith disease, is also known as multiple self-healing squamous epithelioma (MSSE)...
24 January 2011 - by Dr Lucy Freem 
Scientists have identified a gene mutation that is linked to a third of kidney cancers....
24 January 2011 - by Dr Lux Fatimathas 
UK scientists have shown that a single, catastrophic event can induce multiple cancer-causing mutations, simultaneously. The event was first discovered when analysing the genome of a leukaemia patient and subsequently detected in a range of other cancers...
16 August 2010 - by Dr Rachael Panizzo 
Researchers at Yale have identified a potential therapeutic target for cancer in the form of a micro RNA (miRNA) gene that cancer cells, but not normal cells, are dependent on for survival. Inactivating the miRNA causes cancer cell death and tumour regression....
12 July 2010 - by MacKenna Roberts 
Western men who carry a BRCA2 genetic mutation have a six to nine per cent lifetime risk of developing breast cancer, UK researchers have found...
5 July 2010 - by Dr Tamara Hirsch 
Scientists have identified 12 new gene variants associated with type 2 diabetes, according to recent work published in Nature Genetics...
5 June 2010 - by Dr Lux Fatimathas 
Cancer patients in the UK are to be treated with drugs specific to the genetic make-up of their individual tumours. A new initiative, to be launched by the NHS this autumn, will test the tumours of up to 6000 cancer patients a year for known genetic mutations....
15 March 2010 - by Dr Will Fletcher 
Sequencing a patient's genome to find the genetic cause of their inherited disease has finally been proven to be a viable clinical approach in two recent independent studies. For some time gene sequencing has been heralded as ushering in a new era of medicine. However, until now, only around 10 people in the world had had their personal genomes sequenced in full, and all of these were healthy people. Now, in the ten years since the first full genome was sequenced (at a cost of ...
1 March 2010 - by Rose Palmer 
A personalised blood test that could track how a tumour responds to treatment and whether cancer is recurring has been developed by researchers in the U.S...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.